Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Medicines Company has received European Commission Authorization for an expanded use for Angiox or bivalirudin in adult patients with acute coronary syndromes, specifically patients with unstable angina or non-ST segment elevation myocardial infarction planned for urgent or early intervention, when used with aspirin and clopidogrel.
Subscribe to our email newsletter
The approval is based on results from the Acuity trial of 13,819 patients with acute coronary syndromes (ACS). Acuity has demonstrated that Angiox with or without a glycoprotein IIb/IIIa inhibitor (GPI) resulted in similar rates of ischemic clinical outcomes compared to standard therapy of heparin (unfractionated or enoxaparin) plus a GPI.
John Kelley, president and COO of The Medicines Company, said: “With the European Commission decision, the benefits of Angiox can now be extended to the ACS patient populationl.”